)
Magle Chemoswed (MAGLE) investor relations material
Magle Chemoswed Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Q4 2025 saw a significant clean-up of the product portfolio, with major asset write-downs totaling approximately 100 MSEK, impacting EBITDA and depreciation/amortization.
Management prioritized business focus, divesting or writing down underperforming assets, especially in the AXXO product line and Saving Chlora.
Core platforms Magle Chemoswed and Magle Biopolymers performed in line with expectations, with Biopolymers increasing output in a seasonally strong quarter.
Expanded collaboration with Sirtex Medical and an exclusive out-licensing agreement for Magle Biopharma were key strategic moves.
The company is taking steps to strengthen its financial position through planned capital raises and amendments to bond financing.
Financial highlights
Q4 2025 revenue was 78.0 MSEK, down from 84.1 MSEK in Q4 2024; full-year 2025 revenue was 296.6 MSEK, up from 256.2 MSEK in 2024.
Q4 2025 EBITDA was -58.3 MSEK (vs. 20.1 MSEK in Q4 2024); full-year EBITDA was -26.7 MSEK (vs. 58.9 MSEK in 2024).
Q4 2025 EBIT was -120.3 MSEK (vs. -3.9 MSEK in Q4 2024); full-year EBIT was -127.0 MSEK (vs. 23.2 MSEK in 2024).
Q4 2025 net loss was -134.0 MSEK (vs. -0.8 MSEK in Q4 2024); full-year net loss was -159.9 MSEK (vs. 11.9 MSEK profit in 2024).
Earnings per share for Q4 2025 was -6.49 (vs. -0.04 in Q4 2024); full-year EPS was -7.74 (vs. 0.93 in 2024).
Outlook and guidance
Management expects the final audited outcome for 2025 may differ significantly, with a potential negative deviation up to SEK 75 million as asset evaluations continue.
Additional capital of at least SEK 70 million is required by June 2026, subject to the outcome of the first capital raise.
The company is focused on operational efficiency, margin improvement, and a more business-centric model.
- Q3 2025 delivered stronger EBITDA and integration progress, offset by Biopharma market weakness.MAGLE
Q3 202514 Nov 2025 - Revenue up but profitability down in Q2 2025; integration and supply chain issues impacted results.MAGLE
Q2 20251 Aug 2025 - Strong Q3 growth driven by mergers, robust CDMO demand, and one-off PPA income.MAGLE
Q3 202413 Jun 2025 - Q2 sales up 17% as Magle Group advances major mergers to drive future growth.MAGLE
Q2 202413 Jun 2025 - Q1 2025 revenue surged, but integration costs led to a net loss as acquisitions drive future growth.MAGLE
Q1 20256 Jun 2025 - Strong revenue growth and strategic acquisitions drive Magle Group's 2024 performance.MAGLE
Q4 20245 Jun 2025
Next Magle Chemoswed earnings date
Next Magle Chemoswed earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
Frequently asked questions
Explore our global coverage
)
)